TELA Bio, Inc. (TELA)
0.8046
-0.02
(-1.89%)
USD |
NASDAQ |
Nov 16, 13:50
TELA Bio Enterprise Value : 71.19M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 71.19M |
| November 12, 2026 | 72.99M |
| November 11, 2026 | 76.68M |
| November 10, 2026 | 70.28M |
| November 09, 2026 | 73.20M |
| November 06, 2026 | 71.18M |
| November 05, 2026 | 69.38M |
| November 04, 2026 | 71.99M |
| November 03, 2026 | 70.37M |
| November 02, 2026 | 70.25M |
| October 30, 2026 | 70.74M |
| October 29, 2026 | 75.70M |
| October 28, 2026 | 78.23M |
| October 27, 2026 | 77.50M |
| October 26, 2026 | 78.48M |
| October 23, 2026 | 77.73M |
| October 22, 2026 | 79.76M |
| October 21, 2026 | 82.92M |
| October 20, 2026 | 83.37M |
| October 19, 2026 | 77.97M |
| October 16, 2026 | 78.18M |
| October 15, 2026 | 79.76M |
| October 14, 2026 | 83.60M |
| October 13, 2026 | 82.24M |
| October 12, 2026 | 82.92M |
| Date | Value |
|---|---|
| October 09, 2026 | 84.28M |
| October 08, 2026 | 81.57M |
| October 07, 2026 | 82.47M |
| October 06, 2026 | 83.37M |
| October 05, 2026 | 85.63M |
| October 02, 2026 | 85.63M |
| October 01, 2026 | 90.60M |
| September 30, 2026 | 86.08M |
| September 29, 2026 | 81.78M |
| September 28, 2026 | 81.33M |
| September 25, 2026 | 82.68M |
| September 24, 2026 | 83.13M |
| September 23, 2026 | 84.47M |
| September 22, 2026 | 89.40M |
| September 21, 2026 | 84.47M |
| September 18, 2026 | 82.23M |
| September 17, 2026 | 84.02M |
| September 16, 2026 | 79.09M |
| September 15, 2026 | 75.06M |
| September 14, 2026 | 72.81M |
| September 11, 2026 | 69.68M |
| September 10, 2026 | 66.77M |
| September 09, 2026 | 67.04M |
| September 08, 2026 | 63.40M |
| September 04, 2026 | 63.02M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Abbott Laboratories | 215.41B |
| AngioDynamics, Inc. | 480.34M |
| Alphatec Holdings, Inc. | 1.622B |
| AtriCure, Inc. | 2.804B |
| Baxter International, Inc. | 19.36B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.302M |
| Revenue (Quarterly) | 18.96M |
| Total Expenses (Quarterly) | 28.26M |
| EPS Diluted (Quarterly) | -0.1612 |
| Gross Profit Margin (Quarterly) | 64.92% |
| Profit Margin (Quarterly) | -49.06% |
| Earnings Yield | -92.80% |
| Normalized Earnings Yield | -88.32 |